Trials that use: Covariate adjustment
119 results
- KEYNOTE-040Independent statistical analysis of KEYNOTE-040, a randomized phase 3 trial of pembrolizumab versus standard treatment for recurrent or metastatic head and neck squamous cell cancer, including overall survival, progression-free survival, response, statistical…
- KEYNOTE-045Independent statistical analysis of KEYNOTE-045, a randomized phase 3 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in advanced urothelial cancer, including primary and secondary endpoint results and statistical interpretation.
- KEYNOTE-054Independent statistical analysis of KEYNOTE-054, a randomized phase 3 trial of pembrolizumab versus placebo after complete resection of high-risk stage III melanoma, including recurrence-free survival, Cox modeling, confidence intervals, and statistical interpretation.
- KEYNOTE-062Independent statistical analysis of KEYNOTE-062, a randomized phase 3 trial of pembrolizumab monotherapy and pembrolizumab plus standard chemotherapy in advanced gastric adenocarcinoma, including survival, response, quality-of-life, and safety analyses.
- KEYNOTE-177Independent statistical analysis of KEYNOTE-177, the randomized phase 3 trial of pembrolizumab versus standard of care in participants with MSI-H or dMMR stage IV colorectal carcinoma, covering PFS, overall survival, response, statistical…
- KEYNOTE-189Independent statistical analysis of KEYNOTE-189 (NCT02578680), a randomized phase 3 trial evaluating pembrolizumab with pemetrexed-platinum chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
- KEYNOTE-240Independent statistical analysis of KEYNOTE-240, a randomized phase 3 trial of pembrolizumab plus best supportive care versus placebo plus best supportive care in previously systemically treated advanced hepatocellular carcinoma.
- KEYNOTE-355Independent statistical analysis of KEYNOTE-355, evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
- KEYNOTE-361Independent statistical analysis of KEYNOTE-361, the randomized phase 3 trial of pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy alone in urothelial carcinoma, including primary and secondary endpoint analyses, statistical methods,…
- KEYNOTE-394Independent statistical analysis of KEYNOTE-394, a randomized phase 3 trial of pembrolizumab or placebo with best supportive care in Asian participants with previously treated advanced hepatocellular carcinoma.
- KEYNOTE-426Independent statistical analysis of KEYNOTE-426, the randomized phase 3 trial of pembrolizumab plus axitinib versus sunitinib monotherapy in renal cell carcinoma, including primary survival endpoints, response outcomes, statistical methodology, and interpretation.
- KEYNOTE-564Independent statistical analysis of KEYNOTE-564, a randomized phase 3 trial of pembrolizumab versus placebo in the adjuvant treatment of renal cell carcinoma after nephrectomy, including disease-free survival, trial design, statistical methodology, and…
- KEYNOTE-598Independent statistical analysis of KEYNOTE-598, a randomized phase 3 trial of pembrolizumab with ipilimumab versus pembrolizumab with placebo in untreated metastatic non-small cell lung cancer. Includes overall survival, progression-free survival, response, quality…
- KEYNOTE-671Independent statistical analysis of KEYNOTE-671, a randomized phase 3 trial of pembrolizumab with platinum-doublet chemotherapy as neoadjuvant/adjuvant therapy for resectable stage II, IIIA, and resectable IIIB non-small cell lung cancer.
- KEYNOTE-716Independent statistical analysis of KEYNOTE-716, a randomized phase 3 trial of pembrolizumab versus placebo in resected high-risk stage II melanoma, including trial design, recurrence-free survival, safety, statistical methodology, and interpretation.
- KEYNOTE-811Independent statistical analysis of KEYNOTE-811, a randomized phase 3 trial of pembrolizumab plus trastuzumab and chemotherapy versus standard of care in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
- KEYNOTE-826Independent statistical analysis of KEYNOTE-826, evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in women with persistent, recurrent, or metastatic cervical cancer.
- KEYNOTE-859Independent statistical analysis of KEYNOTE-859, a randomized phase 3 trial of pembrolizumab plus chemotherapy versus placebo plus chemotherapy in gastric or gastroesophageal junction adenocarcinoma, including overall survival, progression-free survival, objective response rate,…
- KEYNOTE-966Independent statistical analysis of KEYNOTE-966, evaluating pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin for first-line advanced and/or unresectable biliary tract carcinoma.
- KEYNOTE-A18Independent statistical analysis of KEYNOTE-A18 (NCT04221945), a randomized phase 3 trial of chemoradiotherapy with or without pembrolizumab in locally advanced cervical cancer, including primary time-to-event results, secondary endpoints, cLDA, stratified analysis, and…
- LEAP-002Independent statistical analysis of LEAP-002, the randomized phase 3 trial of lenvatinib plus pembrolizumab versus lenvatinib plus placebo as first-line therapy in advanced hepatocellular carcinoma.
- LUX-Lung 6Independent statistical analysis of LUX-Lung 6, the randomized phase 3 trial comparing afatinib with gemcitabine-cisplatin chemotherapy in first-line non-small cell lung cancer. Includes progression-free survival, response, overall survival, quality-of-life endpoints, statistical methods,…
- LUX-Lung 7Independent statistical analysis of LUX-Lung 7, the randomized phase 2 trial comparing afatinib with gefitinib in first-line EGFR mutation-positive lung adenocarcinoma, including survival, response, quality-of-life, and safety analyses.
- LUX-Lung 8Independent statistical analysis of LUX-Lung 8, the phase 3 randomized trial of afatinib versus erlotinib in squamous cell lung cancer after at least one prior platinum-based chemotherapy. Includes progression-free survival, overall survival,…
- NIAGARAIndependent statistical analysis of the phase 3 NIAGARA trial of durvalumab plus gemcitabine/cisplatin in muscle invasive bladder cancer, covering pathologic complete response, event-free survival, secondary endpoints, methodology, and interpretation.
- ODINIndependent statistical analysis of the ODIN phase 3 trial comparing once-daily versus twice-daily darunavir/ritonavir in early treatment-experienced HIV-1 infected patients, including non-inferiority methodology, logistic regression, ANCOVA, Cox models, confidence intervals, and reported…
- OlympiADIndependent statistical analysis of the OlympiAD phase 3 trial of olaparib monotherapy versus physician's choice chemotherapy in metastatic breast cancer patients with germline BRCA1/2 mutations.
- ORIGINComplete statistical analysis of the ORIGIN phase 3 trial, including its factorial design, cardiovascular and diabetes endpoints, Cox and log-rank methods, odds ratios, confidence intervals, and statistical interpretation.
- PACIFICComplete statistical analysis of the PACIFIC phase 3 trial of MEDI4736 following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer, including primary endpoints, time-to-event methods, secondary analyses, safety,…
- PALOMA-2Independent statistical analysis of PALOMA-2 (NCT01740427), a randomized phase 3 trial of palbociclib plus letrozole versus placebo plus letrozole in postmenopausal women with ER+/HER2- advanced breast cancer.
- PALOMA-4Independent statistical analysis of PALOMA-4, a randomized phase 3 trial comparing palbociclib plus letrozole with placebo plus letrozole in Asian postmenopausal women with ER+/HER2- advanced breast cancer.
- Partners PrEPAn independent statistical analysis of the Partners PrEP phase 3 trial, examining TDF and FTC/TDF for prevention of HIV-1 acquisition in HIV-1 discordant couples, including Cox regression, hazard ratios, safety, longitudinal analyses,…
- PATENT-1Independent statistical analysis of PATENT-1, a randomized phase 3 trial of oral riociguat in patients with pulmonary arterial hypertension, covering its 6-minute walking distance endpoint, ANCOVA, nonparametric and stratified analyses, secondary outcomes,…
- POSEIDONIndependent statistical analysis of the phase 3 POSEIDON trial of durvalumab plus tremelimumab with chemotherapy, durvalumab with chemotherapy, or chemotherapy alone in non-small cell lung cancer, including survival, response, methodology, and interpretation.
- PREVAILIndependent statistical analysis of the phase 3 PREVAIL trial of enzalutamide versus placebo in chemotherapy-naive patients with progressive metastatic prostate cancer, including time-to-event endpoints, response analyses, safety, and statistical interpretation.
- PRoFESSAn independent statistical analysis of PRoFESS (NCT00153062), including its randomized double-blind design, recurrent-stroke endpoints, Cox proportional-hazards analyses, non-inferiority framework, hazard ratios, confidence intervals, and secondary outcomes.
- PROSPERIndependent statistical analysis of the phase 3 PROSPER trial of enzalutamide versus placebo in nonmetastatic castration-resistant prostate cancer, including metastasis-free survival, secondary time-to-event endpoints, PSA response, statistical methodology, and interpretation.
- RAINBOWIndependent statistical analysis of the phase 3 RAINBOW trial of ramucirumab plus paclitaxel versus placebo plus paclitaxel in metastatic gastric adenocarcinoma, including survival, response, quality-of-life, safety, and statistical methodology.
- RATIONALE-301Independent statistical analysis of RATIONALE-301, a randomized phase 3 trial of tislelizumab versus sorafenib in participants with unresectable hepatocellular carcinoma, including overall survival, response, progression, quality of life, and the trial's non-inferiority…
- RE-COVER IIIndependent statistical analysis of RE-COVER II, a randomized phase 3 trial comparing dabigatran etexilate with warfarin for treatment of acute symptomatic venous thromboembolism, including non-inferiority and time-to-event analyses.
- RE-SPECT ESUSIndependent statistical analysis of RE-SPECT ESUS, the randomized phase 3 trial of dabigatran etexilate versus aspirin for secondary stroke prevention after embolic stroke of undetermined source. Includes trial design, time-to-event endpoints, Cox…
- REACHIndependent statistical analysis of the phase 3 REACH trial of ramucirumab plus best supportive care versus placebo plus best supportive care as second-line treatment for hepatocellular carcinoma after sorafenib.
- RED-HFIndependent statistical analysis of the RED-HF phase 3 trial of darbepoetin alfa in heart failure, including trial design, time-to-event endpoints, hazard ratios, KCCQ analyses, safety, methodology, and statistical interpretation.
- RESPIRE 1Independent statistical analysis of RESPIRE 1, a randomized phase 3 trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis, including time-to-exacerbation and exacerbation-rate analyses.
- ROCKET AFIndependent statistical analysis of ROCKET AF, the randomized phase 3 trial of rivaroxaban versus warfarin for prevention of stroke and non-CNS systemic embolism in patients with non-valvular atrial fibrillation.
- RTOG 0617Independent statistical analysis of RTOG 0617, evaluating radiation therapy dose and cetuximab with chemotherapy in newly diagnosed unresectable stage III non-small cell lung cancer, with emphasis on survival, competing risks, safety, and…
- RxPONDERIndependent statistical analysis of the randomized phase 3 RxPONDER trial, including its invasive disease-free survival endpoint, Cox proportional-hazards analyses, menopausal-status interaction, post-hoc distant relapse-free survival results, safety, and statistical interpretation.
- SAILINGComplete statistical analysis of the SAILING phase 3 trial comparing GSK1349572 (dolutegravir) with raltegravir in antiretroviral-experienced, integrase inhibitor-naive adults with HIV infection, including its non-inferiority design, Cochran-Mantel-Haenszel analysis, risk difference, confidence interval,…
- SALSAIndependent statistical analysis of the phase 3 SALSA trial of switching to dolutegravir/lamivudine fixed-dose combination from a current antiretroviral regimen in virologically suppressed adults with HIV-1 infection.
- SHARPIndependent statistical analysis of SHARP, the randomized phase 3 study of sorafenib versus placebo in patients with advanced hepatocellular carcinoma, including its overall survival and symptomatic progression endpoints, stratified log-rank methodology, interim…